Biologics
Total Trials
2
As Lead Sponsor
1
As Collaborator
Total Enrollment
184
NCT03229031
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury
Phase: Phase 3
Role: Lead Sponsor
Start: Mar 7, 2018
Completion: Dec 31, 2026
NCT06328166
The Effect and Safety of Recombinant Fibroblast Growth Factor-1 for Carpal Tunnel Syndrome
Phase: N/A
Role: Collaborator
Start: Mar 22, 2024
Completion: May 30, 2025
Loading map...